Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Ikaros integrates endocrine and immune system development
Shereen Ezzat, Rene Mader, ShunJiang Yu, Terry Ning, Philippe Poussier, Sylvia L. Asa
Shereen Ezzat, Rene Mader, ShunJiang Yu, Terry Ning, Philippe Poussier, Sylvia L. Asa
View: Text | PDF
Article Development

Ikaros integrates endocrine and immune system development

  • Text
  • PDF
Abstract

Ikaros transcription factors are essential regulators of lymphopoiesis and the development of the immune system. We now show that Ikaros is expressed in hormone-producing pituitary corticomelanotroph cells, where it binds the proopiomelanocortin promoter and regulates endogenous gene expression. Loss of Ikaros in vivo results in contraction of the pituitary corticomelanotroph population, reduced circulating adrenocorticotrophic hormone levels, and adrenal glucocorticoid insufficiency. While hemopoietic reconstitution failed to correct this hormonal deficit, the phenotype of reduced body weight and diminished survival was rescued by systemic glucocorticoid-hormone administration. Given the established immunomodulatory properties of glucocorticoid hormones, these findings reveal a novel role for Ikaros in orchestrating immune-endocrine development and function.

Authors

Shereen Ezzat, Rene Mader, ShunJiang Yu, Terry Ning, Philippe Poussier, Sylvia L. Asa

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Identification of Ikaros and Eos expression in pituitary corticotroph ce...
Identification of Ikaros and Eos expression in pituitary corticotroph cells. (A) Northern blotting of polyA RNA from pituitary corticomelanotroph AtT20 pituitary cells using Ikaros cDNA (top) identifies a doublet transcript of 2.7 and 2.5 kb, consistent with Ik1 and Ik2 mRNA expression. This doublet comigrates with that from pro–B lymphocyte–derived RNA. Eos mRNA expression (middle) is detected at much lower levels in AtT20 cells. The GAPDH loading control is shown immediately below. (B) Western blotting using specific antibodies against Ikaros (left) identifies a 52- and 50-kDa doublet that comigrates with that from lymphocytes. Detection with anti-Eos antibody (right) identifies the predicted 57-kDa product in AtT20 cells. The corresponding β-actin loading controls are shown immediately below. (C) Detection of Ikaros by EMSA of a DNA fragment including the Ikaros consensus binding motif, which binds nuclear extracts (NE) from pituitary corticomelanotroph AtT20 similar to those from pro-B lymphocytes. DNA-protein complexes from pituitary AtT20 cells are competed by 100 M excess of wild-type Ikaros oligonucleotide (Ik oligo) and are supershifted by antibody against Ikaros (arrows) and to a lesser extent by an antibody against Eos.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts